The results showed that salirasib treatment of SSc fibroblasts leads to reduced differentiation of fibroblasts into α‐SMA‐positive myofibroblasts and decreased ACTA2 gene expression (p = 0.012) (Figure 4f–j). This evidence concerns the gene ACTA1 and systemic sclerosis.